View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 14, 2020

Russia’s ChemRar reports positive data of Favipiravir in Covid-19

ChemRar Group and The Russian Direct Investment Fund (RDIF) have reported positive data from a multi-centre clinical trial of Favipiravir in patients hospitalised due to Covid-19.

During the randomised, open, comparative trial, 40 patients were treated with the drug. Of these patients, 60% tested negative for coronavirus following five days of treatment, two times higher compared to those on standard therapy.

The findings are said to be consistent with data from studies performed in China, which also revealed a decrease in the disease duration from 11 days to four-five days.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena